Variable | Total (n = 35) | Successfully weaned group (n = 14) | Unsuccessfully weaned group (n = 21) | P value |
---|---|---|---|---|
Gender, number (%) | ||||
 Male | 23(65.7) | 9(64.3) | 14(66.7) | 1.00 |
Age, years, mean ± SD | 57 ± 1 | 51 ± 10 | 60 ± 12 | 0.02* |
Underlying Diseases, number (%) | ||||
 Hypertension | 19(54.3) | 7(50) | 12(57.1) | 0.74 |
 Diabetes | 13(37.1) | 1(7.1) | 12(57.1) | < 0.01* |
 Cerebrovascular disease | 5(14.3) | 3(21.4) | 2(9.5) | 0.37 |
 History of steroid and immunosuppressant within 1 month | 8(22.9) | 4(28.6) | 4(19.0) | 0.69 |
Pregnancy, number (%) | 1(2.9) | 0(0.0) | 1(47.6) | 1.00 |
Onset to NAI | 9 ± 5 | 7 ± 3 | 11 ± 6 | 0.04* |
Onset to ECMO | 10 ± 3 | 10 ± 3 | 10 ± 3 | 0.97 |
Organ support pre-ECMO | ||||
 High-dose vasoactive drugsa, number (%) | 20(57.1) | 6(42.9) | 14(63.6) | 0.31 |
 Rescue ventilation strategiesb, number (%) | 23(65.7) | 6(43.9) | 17(81.0) | 0.03* |
 Duration of IPPV, days, mean ± SD | 5 ± 1 | 2 ± 1 | 6 ± 4 | < 0.01* |
SOFA Score | 9 ± 3 | 7 ± 2 | 10 ± 4 | 0.02* |
Murray Score | 3.6 ± 0.4 | 3.6 ± 0.5 | 3.6 ± 0.4 | 0.95 |
PaO2/FiO2 pre-ECMO, mmHg, mean ± SD | 78 ± 23 | 89 ± 24 | 71 ± 20 | 0.04* |
Duration of ECMO, days, median (IQR) | 8(5–13) | 10(7–13) | 7(3–16) | 0.48 |
Total Duration of IPPV, days, mean ± SD | 20 ± 8 | 23 ± 13 | 18 ± 15 | 0.36 |
Clinical outcomes | ||||
 Mortality, number (%) | 22 (63) | 1 (7.1) | 21 (100) | < 0.01* |
 Length of stay in ICU, days, mean ± SD | 27 ± 14 | 33 ± 12 | 24 ± 14 | 0.081 |
 Length of hospitalization, days, mean ± SD | 31 ± 14 | 39 ± 10 | 27 ± 14 | 0.010* |